Publication for KRAS and ETNK1

Species	Symbol	Function*	Entrez Gene ID*	Other ID	Gene coexpression	CoexViewer
hsa	KRAS	KRAS proto-oncogene, GTPase	3845			[link]
hsa	ETNK1	ethanolamine kinase 1	55500

Pubmed ID	Priority	Text
29358618	0.97	KRAS, JAK2, CSF3R, FLT3, KIT, CALR, MPL, NPM1, CEBPA, IKZF, ETNK1, and SETBP1, by previously described methods.
31448219	0.96	ETNK1, ASUN, FGFR1OP2, TM7SF3, MED21, MRPS35, KLHDC5, CCDC91, FGD4, DNM1L, YASR2, and KRAS) in 12p12.1 were found to have increased copy number and coamplified with KRAS, 88.9% (8/9) genes in our study were included.
	0.66	ETNK1, IAPP, PYROXD1, and KRAS) and 12p13.33 (KDM5A) were associated with worse prognosis in our cohort (Figure 3).
	0.61	ETNK1, IAPP, PYROXD1, KRAS) and 12p13.33 (KDM5A).
28314085	0.90	KRAS, NRAS, JAK2V617F, SUZ12, RUNX1, ETNK1 and EED in aCML.
29531217	0.84	KRAS, JAK2, CSF3R, FLT3, KIT, CALR, MPL, NPM1, CEBPA, IKZF1, ETNK1, and SETBP1 by previously described methods.
28707414	0.63	KRAS, JAK2, CSF3R, FLT3, KIT, CALR, MPL, NPM1, CEBPA, IKZF,ETNK1 and SETBP1, by previously described methods.
31692115	0.55	KRAS, NRAS, SETBP1, CSF3R, ASXL1, and ETNK1 are frequently observed in aCML,5 mutations from SETBP1 and ASXL1 are considered to be associated with poor prognosis till now.5, 6, 7 In therapeutic aspect, mutations in genes related with JAK-STAT, MAPK, ROCK, and SRC family-TNK2 kinase signaling are gaining attention as therapeutic targets recently.5, 8, 9
29722345	0.52	ETNK1, ETV6, EZH2, FBXW7, FLT3, GATA2, IDH1, IDH2, IL7R, JAK1, JAK2, JAK3, KIT, KRAS, MPL, MYD88, NOTCH1, NRAS, PAX5, PDGFRA, PDGFRB, PHF6, PIGA, PTEN, PTPN11, RUNX1, SETBP1, SETD2, SF3B1, SH2B3, SRSF2, STAG2, TET2, TP53, U2AF1, WT1, and ZRSR2, with a median depth of x2000.